Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
Technology appraisal guidance
Reference number: TA983
Published:
Please note that following on from a request received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during mid-March 2023.